Polycystic ovaries is a disproportionate signal in pharmacovigilance data mining of second generation antipsychotics

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 275-276

  Yum, Sun Kyoung ^a   Kim, Tak ^a   Hwang, Michael Y ^b  

^a College of Medicine   (South Korea)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

DATA MINING; DISEASE ASSOCIATION; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; HUMAN; LETTER; MANDATORY REPORTING; OVARY POLYCYSTIC DISEASE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SIGNAL DETECTION; VOLUNTARY REPORTING; CHEMICALLY INDUCED; FEMALE; PROCEDURES; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DATA MINING; FEMALE; HUMANS; PHARMACOVIGILANCE; POLYCYSTIC OVARY SYNDROME; SCHIZOPHRENIA;

EID: 84906937971     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.003     Document Type: Letter

References (10)

1. Böhm R., Höcker J., Cascorbi I., Herdegen T. OpenVigil-free eyeballs on AERS pharmacovigilance data. Nat. Biotechnol. 2012, 30(2):137-138.
2. Chittenden B.G., Fullerton G., Maheshwari A., Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod. Biomed. Online 2009, 19(3):398-405.
3. Council for International Organizations of Medical Sciences (CIOMS) Practical aspects of signal detection in pharmacovigilance. Report of CIOMS Working Group VIII, Geneva 2010, 59.
4. Evans S.J., Waller P.C., Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 2001, 10(6):483-486.
5. FAERS Available at:, (Accessed Apr 15, 2014). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.
6. Hazell L., Shakir S.A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006, 29(5):385-396.
7. Lopez-Gonzalez E., Herdeiro M.T., Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009, 32(1):19-31.
8. Medical Illness and Schizophrenia 2009, American Psychiatric Publishing, Washington DC. Second ed. J.M. Meyer, H.A. Nasrallah (Eds.).
9. Moran L.J., Misso M.L., Wild R.A., Norman R.J. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 2010, 16(4):347-363.
10. van Puijenbroek E.P., Bate A., Leufkens H.G., Lindquist M., Orre R., Egberts A.C. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 2002, 11(1):3-10.